Bristol-Myers Squibb
36 portfolio companies · 6 on the map · $1.4B raised · 6 cities
Portfolio map
5 Bristol-Myers Squibb portfolio companies on the map.
Portfolio companies

Kura Oncology
San Diego
Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
Biotechnology Research$1.2BEst. 2014
Treefrog Therapeutics
Pessac
TreeFrog Therapeutics is a stem cell company that will enable millions of patients to access the medical revolution of cell therapies.
Biotechnology Research$120.9MEst. 2018- NT
Nitrase Therapeutics
Brisbane
Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).
Biotechnology Research$45MEst. 2018 
GlycoEra
Zurich
Advancing Glycan Mediated Therapy
Biotech$12.4MEst. 2020Octant
Emeryville
Octant Bio is a developer of synthetic technology used to improve health and treat disease.
Biotechnology ResearchSeries BEst. 2017
BigHat Biosciences
California
BigHat is a biotech company accelerating the design of next-generation antibody therapeutics to improve human health, positioning itself at the forefront of antibody design; it is backed by a notable group of investors.
BiotechnologySeries BEst. 2019
More portfolio companies
30 more Bristol-Myers Squibb investments we track beyond the map.
Aktis OncologyBoston · Series B
Orna TherapeuticsCambridge · Series A
WaivNew York · Series B
Capstan TherapeuticsSan Diego · Series B
Q32 BioCambridge · Post-IPO Equity
Nuvig TherapeuticsRedwood City · Series B
PathAIBoston · Series C
Ribon TherapeuticsCambridge · Series C
Asher BioSan Francisco · Series C
Be BiopharmaCambridge · Series C
SyntheXSan Francisco · Corporate
K36 TherapeuticsCambridge · Series B
Roswell Park Cancer InstituteBuffalo · Grant
Cajal NeuroscienceSeattle · Series A
AstronauTxReading · Series A
Transition BioCambridge · Series A
Cardior PharmaceuticalsHanover · Series B
Cour Pharmaceuticals DevelopmentSkokie · Series A
Abata TherapeuticsCambridge · Corporate
AttralusSan Francisco · Series B
HiberCellNew York · Series B
Light Horse TherapeuticsSan Diego · Series A
IMIDomicsBarcelona · Series A
ExscientiaOxford · Series D
iVexSolLexington · Series A
Ikena OncologyBoston · Series B
University of North Carolina at Chapel Hill School of MedicineChapel Hill · Grant
Blood Cancer UKLondon · Grant
Instituto OncoguiaSão Paulo · Grant
Drexel UniversityPhiladelphia · Grant
Portfolio map
5 Bristol-Myers Squibb portfolio companies on the map.